Artelo Biosciences raises $9.5M in PIPE, expands SOL treasury management strategy.

Artelo Biosciences has entered into a securities purchase agreement for an at-the-market PIPE, allowing for the purchase and sale of securities at $10.45. The deal includes 906,687 shares of common stock or pre-funded warrants, and three-year warrants to purchase 906,687 shares of common stock at $10.20 per share. Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner and help with treasury management.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways, has entered into a securities purchase agreement for an at-the-market PIPE (private investment in public equity). The deal, priced at $10.45 per share, consists of 906,687 shares of common stock or pre-funded warrants, and three-year warrants to purchase 906,687 shares at an exercise price of $10.20 per share. The expected aggregate gross proceeds amount to approximately $9.475 million [1].

This investment will be used to launch Artelo's Solana ("SOL")-centric digital asset treasury strategy, making it the first publicly traded pharmaceutical company to adopt SOL as a reserve asset. The treasury initiative is part of Artelo's long-term growth strategy, aiming to diversify its treasury while gaining exposure to a next-generation monetary network [1].

Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner and advisor for the treasury strategy. He will work with Artelo through his company, CUBE, to secure storage, staking, and active DeFi execution of Artelo's digital asset treasury [1].

Artelo's Board has approved the expansion of its SOL treasury strategy over time, ensuring adequate working capital for the continued development and commercialization of its proprietary therapeutics. The move signals Artelo's commitment to innovative and disciplined capital management while entering the digital asset space [1].

The closing of the PIPE is expected to occur on or about August 5, 2025, subject to customary closing conditions [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/04/3126467/0/en/Artelo-Biosciences-Announces-9-475-Million-At-the-Market-Private-Placement-to-Initiate-Solana-Treasury-Strategy-Becoming-First-Publicly-Traded-Pharmaceutical-Company-to-Adopt-SOL-a.html